share_log

Alexion, AstraZeneca Rare Disease Announces Agreement With Pan-Canadian Pharmaceutical Alliance For Koselugo In Treatment Of Paediatric Patients With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

Benzinga ·  Dec 18 09:11
Alexion, AstraZeneca Rare Disease Announces Agreement With Pan-Canadian Pharmaceutical Alliance For Koselugo In Treatment Of Paediatric Patients With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment